Puma Biotechnology (PBYI) closed FY 2025 with Q4 revenue of US$75.5 million and basic EPS of US$0.27, alongside net income of US$13.4 million. Its trailing 12 month revenue came in at US$228.4 million with basic EPS of US$0.62 and net income of US$31.1 million. Over recent periods, the company has seen quarterly revenue range from US$46.0 million to US$80.5 million and basic EPS move between US$0.06 and US$0.98. This gives investors a clear view of how earnings scale with top line performance. With net profit margin edging higher over the last year and forecasts calling for earnings pressure ahead, this set of results puts the spotlight firmly on how durable those margins really are.

See our full analysis for Puma Biotechnology.

With the headline numbers on the table, the next step is to weigh them against the most common stories around Puma Biotechnology, highlighting where the data supports those narratives and where it pushes back.

TTM profit growth slows sharply

• Trailing 12 month net income is US$31.1 million with basic EPS of US$0.62, compared with five year earnings growth of 72.5% per year and one year growth of 2.8%.
• Consensus narrative flags rising R&D and higher costs as a risk to future profitability, and the latest trailing figures partly echo that, as:
  • Net profit margin only edges up from 13.1% to 13.6% while earnings growth slows to 2.8% in the most recent year despite that higher margin.
  • Analysts expect earnings to decline by about 11.2% per year over the next three years, which sits in clear contrast to the strong 72.5% multi year growth rate.

Single product reliance vs FY 2025 revenue mix

• Across FY 2025, quarterly revenue ran between US$46.0 million and US$75.5 million, with basic EPS ranging from US$0.06 to US$0.27 as net income moved between US$3.0 million and US$13.4 million.
• Bears focus on the heavy dependence on NERLYNX and pressure on enrollments, and the pattern in these numbers gives that view some backing, because:
  • Revenue across the last six quarters swings from US$46.0 million up to US$80.5 million, so earnings, which move between US$3.0 million and US$20.3 million over the same window, are tightly coupled to a single revenue stream rather than multiple products smoothing results.
  • Guidance pointing to higher gross to net adjustments and lower royalty contributions means any softness in NERLYNX volumes could have a direct effect on both revenue and EPS bands investors have seen in the recent history.

If you want to see how optimistic investors are connecting these earnings to Puma Biotechnology's future pipeline potential, check out what the bullish side is saying in 🐂 Puma Biotechnology Bull Case.

Low P/E and DCF gap vs cautious forecasts

• The shares trade at US$5.70 with a P/E of 9.2x, compared with peers on 41.9x, the biotech industry on 23x, and a DCF fair value of roughly US$25.14.
• Bulls point to this valuation gap as an opportunity, but the forecast data adds an important tension to that story, because:
  • Earnings are expected to decline by about 11.2% each year over the next three years while revenue is forecast to slip by 0.8% per year, which helps explain why the market is not paying peer level multiples today.
  • The current P/E of 9.2x sits far below both peer and industry averages even with net margin at 13.6%, so for the bullish view to play out, investors would need confidence that the projected earnings declines do not fully materialize or that later pipeline contributions offset them.

Skeptics think the low P/E simply reflects those earnings decline forecasts, so if you want to understand that side of the argument in more detail, have a look at 🐻 Puma Biotechnology Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Puma Biotechnology on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of caution and optimism running through this update, it is worth checking the numbers yourself and deciding where you stand. To see how that balance of concerns and potential upsides looks in one place, take a look at the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Puma Biotechnology's reliance on a single product, cautious earnings forecasts and tight margin movement leave investors exposed if the current profit profile comes under pressure.

If that concentration risk feels a bit too sharp right now, take a few minutes to check out 76 resilient stocks with low risk scores that spread business and earnings risk more evenly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.